S
Sneha Ramakrishna
H-index:21
Citation Count:5,034
Views:0
Biography
No content for now.
Education
No content for now.
Work Experience
No content for now.
Honors & Awards
No content for now.
Docetaxel-Induced Myositis in a 16-Year-Old Male With Rhabdomyosarcoma: Case Report and Literature Review
多西他赛诱导的16岁男性横纹肌肉瘤患者肌炎:病例报告及文献综述
Linking HLA-DRB1*15 to Severe Dress-like Inflammatory Toxicities Following Tocilizumab after CAR-T Therapy
将HLA-DRB1*15与托珠单抗治疗后的CAR-T疗法相关严重DRESS样炎症性毒性反应相联系
Imaging the efficacy and side effects of CAR T-cell therapy in children and young adults
评估CAR T细胞疗法在儿童和年轻成人中的疗效和副作用
Cancer Imaging
IF3.5
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer
CAR T细胞治疗在儿童、青少年和青年癌症患者中的典型作用
EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING
B7-H3免疫组织化学在高级别胶质瘤中用于嵌合抗原受体T细胞预测性检测的评价
NEURO-ONCOLOGY
IF13.4
HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
人源化抗CAR抗体影响弥漫性中线胶质瘤中GD2-CAR T细胞的持久应答
NEURO-ONCOLOGY
IF13.4
SINGLE-CELL LANDSCAPE OF B7H3-CAR T THERAPY IN GLIOMA: MECHANISMS OF RESISTANCE AND SIGNATURES OF LONG-TERM RESPONSE
单细胞景观揭示B7H3-CAR T疗法在胶质瘤中的抗药机制及长期应答特征
NEURO-ONCOLOGY
IF13.4
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
CD22 CAR T细胞在B-ALL中的治疗效果:两种制造策略的故事
Cytotherapy
IF3.2
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
静脉和颅内GD2-CAR T细胞用于H3K27M弥漫性中线胶质瘤
Nature
IF48.5
TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
肿瘤炎症相关神经毒性 (TIAN): 中枢神经系统肿瘤免疫治疗患者的毒性综合征
NEURO-ONCOLOGY
IF13.4
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities
启发研讨会第4B部分: 嵌合抗原受体T细胞相关研究-已确定的发现和未来的优先事项

